Alnylam Pharmaceuticals (ALNY) Other Non Operating Income (2009 - 2026)

Alnylam Pharmaceuticals has reported Other Non Operating Income for 18 years, with the latest figure at -$4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 146.73% year-over-year to -$4.3 million; the trailing twelve-month figure through Mar 2026 stood at -$88.2 million (up 43.78% YoY), and the FY2025 full-year result was $5.2 million, up 102.88% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$4.3 million, down from -$3.4 million in the prior quarter.
• The five-year high for Other Non Operating Income was $55.0 million in Q4 2022, with the low at -$80.8 million in Q4 2024.
• Historically, Other Non Operating Income has averaged -$29.4 million across 5 years, with a median of -$29.5 million in 2024.
• The largest YoY upside for Other Non Operating Income was 2783.8% in 2022 against a maximum downside of 382.89% in 2022.
• Alnylam Pharmaceuticals' Other Non Operating Income stood at $55.0 million in 2022, then slumped by 136.99% to -$20.4 million in 2023, then plunged by 297.26% to -$80.8 million in 2024, then surged by 95.84% to -$3.4 million in 2025, then slipped by 27.83% to -$4.3 million in 2026.
• The last three Other Non Operating Income figures came in at -$4.3 million (Q1 2026), -$3.4 million (Q4 2025), and -$74.1 million (Q3 2025), per Business Quant data.